	US 12,447,177 B2
	Methods for managing adverse events in patients with inflammation
Andrew Dunham, Tower Lakes, IL (US); Tatsuro Yoshida, West Newton, MA (US); and Samuel O. Sowemimo-Coker, Dix Hills, NY (US)
Assigned to Hemanext Inc., Lexington, MA (US)
Appl. No. 17/292,597
Filed by Hemanext Inc., Lexington, MA (US)
PCT Filed Nov. 14, 2019, PCT No. PCT/US2019/061565 § 371(c)(1), (2) Date May 10, 2021, PCT Pub. No. WO2020/102602, PCT Pub. Date May 22, 2020.
Claims priority of provisional application 62/768,667, filed on Nov. 16, 2018.
Prior Publication US 2021/0401883 A1, Dec. 30, 2021
Int. Cl. A61K 35/14 (2015.01); A61P 7/06 (2006.01)

CPC A61K 35/14 (2013.01) [A61P 7/06 (2018.01)]

9 Claims

1. A method of treating elevated c-reactive protein (CRP) in a patient in need thereof comprising administering stored oxygen reduced blood having an oxygen saturation of 20% or less during storage to a patient in need thereof having both elevated CRP and inflammation, wherein the elevated CRP level is between 5 and 10 milligrams per liter (mg/L) prior to the administering, and wherein the administering reduces the elevated CRP level in the patient in need thereof by at least 20% relative to a CRP level of a patient having both elevated CRP and inflammation and having been administered conventionally stored, non-oxygen reduced blood.